Related Experiment Video
Updated: Jan 13, 2026

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
Published on: April 23, 2019
When Safety-Net Programs Compete: Medicaid, 340B, And The Battle Over Drug Discounts
Sayeh Nikpay1, Mikayla Reinke2, Elizabeth Watts3
1Sayeh Nikpay (snikpay@umn.edu), University of Minnesota, Minneapolis, Minnesota.
Abstract:
The Medicaid Drug Rebate Program and the 340B Drug Pricing Program are generally understood as separate efforts to promote drug affordability-one by directly subsidizing low-income patients through insurance coverage (Medicaid) and the other by indirectly subsidizing safety-net clinics and hospitals (340B). Yet they interact in ways that can unintentionally raise costs for Medicaid. This Policy Insight examines how this interaction occurs, introduces two policy strategies to mitigate the interaction, and summarizes the use of these strategies across states as of 2024. We conclude with recommendations for how policy makers can weigh the costs and benefits of states' efforts to preserve Medicaid savings against lost revenue for 340B-participating organizations.
Related Concept Videos
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Drug Control Governance: Regulatory Bodies and Their Impact
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Drug Products: Biologics, Biosimilars and Interchangeables
Pharmacokinetics in Pediatric Patients: Drug Excretion
Drug Regulation

